Search clinical trials for: Org 50081

Total 6095 results

Ablynx, a Sanofi company

Completed

Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura (HERCULES)

Acquired Thrombotic Thrombocytopenic Purpura

United States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Hungary, Israel, Italy, Netherlands, Spain, Switzerland, Turkey, United Kingdom
Sihuan Pharmaceutical Holdings Group Ltd.

Completed

Benapenem PK Phase Ib Multiple-dose Study

Health, Subjective
Sihuan Pharmaceutical Holdings Group Ltd.

Completed

Single-dose PK Study of Benapenem In Healthy Subjects

Healthy Subject
Sihuan Pharmaceutical Holdings Group Ltd.

Completed

Multiple-dose Tolerability and Pharmacokinetic Studies of Benapenem inClinical Healthy Subjects

Healthy Subject
Dr. August Wolff GmbH & Co. KG Arzneimittel

Completed

Use Test: Dermowas Body Lotion pH 4 vs. pH 5.8

Healthy

Germany
Intellia Therapeutics

Terminated

Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States, United Kingdom
Duramed Research

Completed

A Clinical Trial to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001

Respiratory Tract Diseases

United States
Ablynx, a Sanofi company

Completed

Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) (TITAN)

Acquired Thrombotic Thrombocytopenic Purpura

United States, Austria, Belgium, France, Germany, Israel, Italy, Spain, Switzerland, United Kingdom, Bulgaria, Romania, Australia
AtlasMedx, Incorporated

Active, not recruiting

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Homologous Recombination Deficiency | Advanced Malignant Neoplasm

United States
G2GBio, Inc.

Completed

Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Donepezil From Single Dose of GB-5001 IM Depot and Aricept® Oral Tablets in Healthy Male Volunteers

Alzheimer Disease

Canada
Ablynx, a Sanofi company

Completed

Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients

Unstable Angina | Non ST Segment Elevation Myocardial Infarction (NSTEMI) | Stable Angina (Associated With High Risk PCI)

Poland, Belgium, Germany, Israel, Austria, Switzerland, Czechia
University of Calgary

Completed

Adjusting Fluid Removal Based on Blood Volume in Hemodialysis: A Randomized Study

End Stage Renal Failure on Dialysis | Intradialytic Hypotension

Canada
Dong-A Pharmaceutical Co., Ltd.

Completed

A Randomized, Open Label, Single Dose, 2-Way Cross-over Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Exforge® and G-0081 in Healthy Male Volunteers

Healthy Male Volunteer
Merck Sharp & Dohme LLC

Completed

Fifty Two Week Extension Trial of Org 50081 (Esmirtazapine) in the Treatment of Insomnia (P05708)

Insomnia
Merck Sharp & Dohme LLC

Completed

Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706) (RUBY)

Insomnia
Merck Sharp & Dohme LLC
Parexel

Completed

A Six Week, Double-Blind Randomized, Efficacy and Safety, Sleep Lab Trial With Esmirtazapine (Org 50081) (P05707)

Insomnia
National Taipei University of Nursing and Health...

Recruiting

The Effect of Digital Reminiscence Therapy on People With Mild and Moderate Dementia

Dementia

Taiwan
Merck Sharp & Dohme LLC

Completed

Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013)

Vasomotor Symptoms | Menopause | Postmenopausal Symptoms
Merck Sharp & Dohme LLC

Completed

Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012)

Vasomotor Symptoms | Menopause
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Effect of Single and Multiple Doses Org 50081 and a Single Dose of Zopiclone on Next-day Driving Ability and Psychomotor Performance in Healthy Volunteers. (P05794) (COMPLETED)

Mental Disorders | Sleep Initiation and Maintenance Disorders
Centre Hospitalier Universitaire de Saint Etienne

Withdrawn

Assessing the Impact of Two Methods of Continuous Veno-venous Hemodiafiltration on Time Nursing Work in Intensive Care

Acute Renal Failure
Weill Medical College of Cornell University

Completed

Safety Study of ORG 34517 for Major Depression With Psychotic Features

Psychotic Disorders | Major Depressive Disorder

United States
Abbott Medical Devices

Not yet recruiting

External Sensing and Neuromodulation to Assess Diabetic Pain Outcomes (XANADO) (XANADO)

Chronic Pain

United States
Merck Sharp & Dohme LLC

Completed

A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Psychotic Major Depression (28130)(P05845) (Hermes)

Depression | Psychotic Disorders | Depressive Disorders
Origo Biopharma

Completed

First in Human Study of ORG-129 in Healthy Volunteers

Healthy Volunteers

Spain
Guangzhou General Hospital of Guangzhou Military...
Guangdong Provincial Hospital of Traditional Chinese Medicine

Recruiting

Pharmacokinetics of Sugammadex for the Reversal of Moderate Neuromuscular Blockade in Patients During Renal Transplantation

Pharmacokinetics

China
Merck Sharp & Dohme LLC

Completed

A Follow up Safety Study of Patients Who Participated in Previous Studies of the Drug Org 24448 (Study P05719)(COMPLETED)

Psychosis
Merck Sharp & Dohme LLC

Completed

Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)

Depression | Psychotic Disorders | Depressive Disorders
Bellerophon BCM LLC

Completed

IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction (PRESERVATION-1)

Congestive Heart Failure | Acute Myocardial Infarction | ST-Elevation Myocardial Infarction

United States, Spain, France, Belgium, Australia, Israel, Canada, Germany, Poland
Dennis Charney
National Institutes of Health (NIH)

Withdrawn

Randomized, Placebo-controlled Trial of an AMPAkine in Major Depressive Disorder

Major Depressive Disorder
Merck Sharp & Dohme LLC

Terminated

Org 25935 Versus Placebo as Augmentation to Cognitive-behavioral Therapy to Treat Panic Disorder (P05705)

Panic Disorder
Merck Sharp & Dohme LLC

Completed

Efficacy, Pharmacokinetics and Safety of Org 25969 in Subjects With Normal or Impaired Renal Function (19.4.304)(P05948)(COMPLETED)

Anesthesia, General
Merck Sharp & Dohme LLC

Completed

Comparison of 4.0 mg/kg Sugammadex at 1-2 Post Tetanic Counts (PTC) in Renal or Control Patients (19.4.328)(P05769)

Anesthesia
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy Evaluation of Sugammadex in Cardiac Patients (19.4.309)(P05934)

Anesthesia
Guangzhou General Hospital of Guangzhou Military...

Recruiting

Pharmacokinetics of Sugammadex in Reversal of Vecuronium-induced Neuromuscular Blockade in Patients During Laparoscopic Surgery

Pharmacokinetics

China
Organon and Co

Completed

Study to Investigate the Optimal Dose of Org 36286 to Induce Monofollicular Ovulation in Women With WHO Group II Anovulatory Infertility (P07016)

Infertility
Merck Sharp & Dohme LLC

Completed

Comparison of the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616; Org 25969) in Elderly Participants With Adult Participants (MK-8616-029)

Anesthesia, General
Organon and Co

Completed

A Trial of Single Dose Corifollitropin Alfa's Ability to Induce Multiple Follicular Growth During the First Week of Controlled Ovarian Stimulation for IVF or ICSI (38833)(P05788) (Realize)

In Vitro Fertilization
Merck Sharp & Dohme LLC

Completed

Adjuvant Treatment With a Glycine Uptake Inhibitor in Participants With Negative Symptoms of Schizophrenia (P05695) (MK-8435-001) (GIANT)

Schizophrenia
University of Plymouth
Veeda Clinical Research; Organon Teknika

Completed

First Administration to Man Of Org 25435 a New Intravenous Anesthetic

Anaesthesia

United Kingdom
Universidad El Bosque, Bogotá
Gloria Lafaurie; Carlos Leal

Completed

Horizontal Ridge Augmentation in Mandible Usign ROG + ESWT

Bone Regeneration

Colombia
Guangzhou General Hospital of Guangzhou Military...

Recruiting

Effect of Sugammadex for Reversal of Rocuronium-induced Neuromuscular Block on Perioperative Management of Awake Craniotomy

Brain Tumors

China
National Institute of Mental Health (NIMH)

Terminated

Org 24448 to Treat Major Depression

Depression

United States
Washington University School of Medicine
The Craig H. Neilsen Foundation

Completed

Motor Learning Approach for Manual Wheelchair Users

Spinal Cord Injuries

United States
Merck Sharp & Dohme LLC

Completed

Use of Sugammadex Administered at 5 Minutes After Administration of 1.2 mg/kg Esmeron® (19.4.205)(P05942)

Anesthesia, General
Guangzhou General Hospital of Guangzhou Military...

Unknown

Pharmacokinetics and Pharmacodynamics of Sugammadex in Reversal of Vecuronium-induced Neuromuscular Blockade

Pharmacokinetics | Pharmacodynamics

China
Merck Sharp & Dohme LLC

Completed

A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part A: Japanese Participants (P05956)

Anesthesia, General
Organon and Co
CRS Mannheim GmbH

Completed

A Trial to Assess the Pharmacokinetic Profile (e.g., Uptake, Distribution and Excretion of a Substance in the Body) of Nomegestrol Acetate (NOMAC), Estradiol (E2) and Estrone (E1) After Multiple and Single Dose Administration of the Combined Oral Contraception NOMAC-E2 (COMPLETED)(P05822)

Healthy
Orion Corporation, Orion Pharma

Completed

Early Phase I Microdosing Study of ORM-14540 and ORM-12741

Healthy

Finland
Merck Sharp & Dohme LLC

Completed

Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698)

Neuromuscular Blockade

3

Subscribe